Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
However, all integrase inhibitors were associated with similar weight gain.
This is according to a three-year study in which people switched from a stable HIV regimen to Delstrigo.
The insert contained the antiretrovirals tenofovir alafenamide, known as TAF, and Vitekta (elvitegravir).
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
An OK would add an indication for the use of these HIV medications among those switching from stable regimens.
According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.
This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.
People who take integrase inhibitors are less likely to stop them due to health issues.
Tivicay (dolutegravir) is a next-generation integrase inhibitor.
Those on Tybost-boosted Vitekta are more than twice as likely as those taking Tivicay to switch meds because of adverse health events.
More research is needed to determine the metabolic implications of this apparent association and how it may drive diabetes.
In a small study, the drop in seminal viral load in men who started treatment with PIs lagged behind that of men going on other HIV meds.
Researchers have succeeded in charting the structure of a tool central to HIV’s effort to splice its genetic code into a human cell’s DNA.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.